Holen Sie sich die Stockscreener-App
1.04
2.97%
0.03
Handel nachbörslich:
1.02
-0.02
-1.92%
Schlusskurs vom Vortag:
$1.01
Offen:
$0.9999
24-Stunden-Volumen:
733.91K
Relative Volume:
1.67
Marktkapitalisierung:
$50.54M
Einnahmen:
$1.14M
Nettoeinkommen (Verlust:
$-60.82M
KGV:
-0.7797
EPS:
-1.3338
Netto-Cashflow:
$-60.29M
1W Leistung:
+30.51%
1M Leistung:
+64.58%
6M Leistung:
-48.77%
1J Leistung:
+48.93%
1-Tages-Spanne:
$0.9999
$1.14
1-Wochen-Bereich:
$0.7717
$1.14
52-Wochen-Spanne:
$0.5301
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Firmenname
Werewolf Therapeutics Inc
Sektor
Branche
Telefon
617-952-0555
Adresse
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.04 | 49.08M | 1.14M | -60.82M | -60.29M | -1.3338 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-04-03 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-24 | Eingeleitet | Wedbush | Outperform |
| 2023-06-06 | Fortgesetzt | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-25 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-25 | Eingeleitet | Jefferies | Buy |
| 2021-05-25 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten
HOWL Technical Analysis & Stock Price Forecast - Intellectia AI
Investment Report: Is now the right time to enter Werewolf Therapeutics IncWeekly Trend Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Werewolf Therapeutics Faces Nasdaq Delisting Risk After Falling Below $1 Minimum Bid Price - TipRanks
HOWL Forecast, Price Target & Analyst Ratings | WEREWOLF THERAPEUTICS INC (NASDAQ:HOWL) - ChartMill
HOWL PE Ratio & Valuation, Is HOWL Overvalued - Intellectia AI
HOWL Should I Buy - Intellectia AI
Aug Action: Is now the right time to enter Werewolf Therapeutics Inc2026 Technical Patterns & Accurate Buy Signal Alerts - baoquankhu1.vn
Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - bitget.com
Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c) - tipranks.com
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Earnings - AlphaStreet
Werewolf Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Werewolf Therapeutics Reports 2025 Financial Results and Advances Cancer Therapy Clinical Pipeline - geneonline.com
Werewolf Therapeutics (HOWL) faces going‑concern risk while IL‑2 and IL‑12 candidates show early responses - Stock Titan
Werewolf Therapeutics 10-K: Revenue $0M, Net Loss $(60.82)M - TradingView
Earnings Scheduled For March 27, 2026 - Benzinga
HOWL: Strategic review underway with improved financials and continued progress in oncology pipeline - TradingView
Werewolf Therapeutics (NASDAQ: HOWL) cuts 2025 loss and launches strategic review - Stock Titan
Aug Drivers: Is Werewolf Therapeutics Inc a speculative investment2026 Technical Patterns & Low Risk High Reward Ideas - baoquankhu1.vn
Biotech 'Lowballed' Landlord On Lease Exit, Suit Says - Law360
Werewolf Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
HOWL Stock Price, Quote & Chart | WEREWOLF THERAPEUTICS INC (NASDAQ:HOWL) - ChartMill
Aug Setups: Is Intelligent Bio Solutions Inc part of any major index2026 Trends & Weekly Breakout Watchlists - baoquankhu1.vn
Michael J. Urban Net Worth (2026) - gurufocus.com
Werewolf Therapeutics (HOWL) eyes 2026 catalysts following FDA guidance and encouraging INDUKINE results - MSN
RSI Check: Is Werewolf Therapeutics Inc stock trending bullishTrade Exit Report & Growth Oriented Trading Recommendations - baoquankhu1.vn
Analyst Downgrade: Is now the right time to enter Werewolf Therapeutics IncLayoff News & Real-Time Volume Triggers - baoquankhu1.vn
Werewolf Therapeutics (HOWL) finance VP reports stock and option holdings on Form 3 - Stock Titan
Werewolf Therapeutics stock rises over 5% after hours on workforce reduction, including executives - MSN
Werewolf Therapeutics (HOWL) Stock Analysis Report | Financials & Insights - Benzinga Japan
Werewolf Therapeutics (HOWL) price target decreased by 10.86% to 5.30 - MSN
Published on: 2026-03-05 15:55:35 - baoquankhu1.vn
Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives - Stocktwits
HOWL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Tuesday - Defense World
HOWL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Is now the right time to enter Werewolf Therapeutics IncTrade Entry Report & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Werewolf Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Werewolf Therapeutics announces plan to explore strategic alternatives - MSN
Werewolf Therapeutics explores sale and strategic alternatives - Investing.com India
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives - The Manila Times
Werewolf Therapeutics Begins Strategic Alternatives Review Process - TipRanks
Werewolf Therapeutics (HOWL) starts review of strategic options with Piper Sandler - Stock Titan
Werewolf Therapeutics explores sale and strategic alternatives By Investing.com - Investing.com South Africa
Werewolf to Explore Strategic Alternatives, Engages Piper Sandler as Exclusive Advisor - TradingView
Levels Update: Does Werewolf Therapeutics Inc have strong EBITDA marginsJuly 2025 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
HOWL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Why Werewolf Therapeutics Inc. stock could rally in 2025Portfolio Gains Summary & Smart Swing Trading Techniques - mfd.ru
IPO Launch: Does Werewolf Therapeutics Inc have strong EBITDA margins2025 Analyst Calls & Risk Controlled Daily Plans - baoquankhu1.vn
Werewolf Therapeutics stock falls after announcing 64% workforce reduction By Investing.com - Investing.com Canada
Finanzdaten der Werewolf Therapeutics Inc-Aktie (HOWL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Werewolf Therapeutics Inc-Aktie (HOWL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| EVNIN LUKE | Director |
Jan 13 '26 |
Sale |
0.55 |
43,198 |
23,759 |
2,266,671 |
| EVNIN LUKE | Director |
Jan 15 '26 |
Sale |
0.55 |
37,413 |
20,577 |
2,198,642 |
| EVNIN LUKE | Director |
Jan 14 '26 |
Sale |
0.57 |
30,616 |
17,451 |
2,236,055 |
| EVNIN LUKE | Director |
Jan 12 '26 |
Sale |
0.57 |
58,980 |
33,619 |
2,309,869 |
| EVNIN LUKE | Director |
Jan 09 '26 |
Sale |
0.61 |
24,678 |
15,054 |
2,368,849 |
| EVNIN LUKE | Director |
Jan 08 '26 |
Sale |
0.63 |
7,716 |
4,861 |
2,393,527 |
| EVNIN LUKE | Director |
Jan 06 '26 |
Sale |
0.65 |
40,761 |
26,495 |
2,413,158 |
| EVNIN LUKE | Director |
Jan 05 '26 |
Sale |
0.64 |
18,378 |
11,762 |
2,453,919 |
| EVNIN LUKE | Director |
Jan 07 '26 |
Sale |
0.64 |
11,915 |
7,626 |
2,401,243 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):